Skip to main content

A Study of Eptinezumab in Pediatric Participants With Episodic Migraine

Recruiting · Phase 3 · NCT05897320

Conditions: Episodic Migraine

At a glance

Research payments reported, 2025
$399,306
U.S. investigators named
14
Sites paid
13
Planned or actual enrollment
315

About the trial

Sponsor
H. Lundbeck A/S
Tested
Eptinezumab (drug), Placebo (drug)
Dates
Started 2023-06-08; completion 2027-08-31
Results posted
Not yet

The main goal of this trial is to learn whether eptinezumab helps reduce the number of days with episodic migraine in pediatric participants.

From ClinicalTrials.gov, last updated 2026-10-14. Full record, eligibility and contacts (opens in a new tab)

Industry funding

H. Lundbeck A S reported $399,306 in research payments for this study in 2025 (132 payments).

Products named: Vyepti

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

  • Neostart Corporation DBA Aga C $79,940
  • Northwest Florida Clinical Res $67,096
  • Cincinnati Childrens Hospital $49,576
  • Medical College of Wisconsin $49,548
  • Akron Children's Hospital, OH $40,831
  • Multicare Neuroscience $27,832
  • The University of South Florida $26,058
  • Michigan Headache and Neurological Institute $21,685
  • Road Runner Research LTD $20,067
  • Jefferson Health $7,924
  • Childrens Specialty Group PLLC $3,685
  • University of Maryland Baltimore $3,408
  • Onsite Clinical Solutions LLC $1,655

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.